Literature DB >> 3622781

Preoperative prediction of extent and prognosis of gastric carcinoma by four serum proteins and erythrocyte sedimentation rate.

C W Janssen, H Maartmann-Moe, R T Lie.   

Abstract

In 195 patients with gastric carcinoma the preoperative ESR and serum concentrations of IgG, C4, C1-INH and CEA varied significantly with the extent of disease. Extent of disease and prognosis were predicted from these variables by discriminant analysis. The discriminant rules were tested on the same patients in an unbiased way. Metastases or no metastases were correctly predicted in 75% of the patients. By an appropriate prior distribution 93% of the patients without metastases were identified. The disease extent was also predicted in subgroups of patients with and without metastases. Survival was correctly predicted preoperatively in 66% of the patients and 83% of the patients with a fair prognosis were identified. Of the patients preoperatively allocated to the non-survival group 94% did actually die during follow-up. When used in addition to other available information, our discriminant rules will contribute to the quality of the preoperative evaluation of patients with gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3622781

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

1.  Prognostic value of neutrophil to lymphocyte ratio for gastric cancer.

Authors:  Zhi-De Hu; Yuan-Lan Huang; Bao-Dong Qin; Qing-Qin Tang; Min Yang; Ning Ma; Hai-Tao Fu; Ting-Ting Wei; Ren-Qian Zhong
Journal:  Ann Transl Med       Date:  2015-03

2.  Serum C1-esterase inhibitor, an essential and independent prognosticator of gastric carcinoma.

Authors:  C W Janssen; R T Lie; H Maartmann-Moe; R Matre
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

3.  The influence of the host on the course of gastric carcinoma.

Authors:  C W Janssen; R T Lie; C F Bassøe; H Maartmann-Moe; R Matre
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.